Bavarian Nordic第三季收入18.05亿丹麦克朗：旅行健康收入增22%至11.44亿克朗、EBITDA利润率34.4%，11月13日发布
疫苗公司 Bavarian Nordic 于 2026 年 11 月 13 日公布截至 2026 年 9 月 30 日的第三季与前九个月中期业绩。以下数字均出自公司业绩稿正文，稿件不作投资建议。
第三季收入为 18.05 亿丹麦克朗，上年同期为 17.95 亿丹麦克朗。
旅行健康收入增 22% 至 11.44 亿丹麦克朗，若剔除已终止合作的影响增幅为 32%，主要由狂犬病疫苗 RabAvert 与 Rabipur 销售 8.86 亿丹麦克朗、增 37% 带动，基孔肯雅热疫苗 Vimkunya 收入 7300 万丹麦克朗、增 146% 亦有支持。公共防范收入为 6.06 亿丹麦克朗。
第三季 EBITDA 为 6.21 亿丹麦克朗，利润率 34.4%。前九个月总收入为 48.97 亿丹麦克朗、增 2%。公司维持 10 月 8 日上调后的全年指引，预计总收入约 61 亿丹麦克朗、EBITDA 利润率约 32%。
Bavarian Nordic Third-Quarter Revenue of DKK 1,805 Million: Travel Health Revenue Rose 22 Percent to DKK 1,144 Million With an EBITDA Margin of 34.4 Percent, Released November 13
Vaccine company Bavarian Nordic announced its interim financial results for the third quarter and first nine months of 2026 on November 13, 2026. All figures below are from the body of the company's results release, and this report offers no investment advice.
Revenue in the third quarter was DKK 1,805 million, compared to DKK 1,795 million in the third quarter of 2025.
Travel Health revenue increased by 22 percent, or 32 percent when adjusting for discontinued partnerships, to DKK 1,144 million, primarily driven by continued strong RabAvert and Rabipur sales of DKK 886 million, up 37 percent, and supported by the continued launch of Vimkunya at DKK 73 million, up 146 percent. Public Preparedness revenue reached DKK 606 million in the quarter.
EBITDA in the third quarter was DKK 621 million, corresponding to an EBITDA margin of 34.4 percent. Total revenue for the first nine months was DKK 4,897 million, an increase of 2 percent. The company maintained its upgraded full-year guidance, expecting total revenue of approximately DKK 6,100 million and an EBITDA margin of approximately 32 percent.
来源：Bavarian Nordic
发布：GSM·美国（发布链接）
图片来源：图：Bavarian Nordic相关图(资料图)。作者与授权：Jacob van Ruisdael，Public domain，维基共享资源。 / Photo: Image related to Bavarian Nordic (file photo). Credit: Jacob van Ruisdael, Public domain, Wikimedia Commons.
GSM Global · 本篇英文版 English edition of this story
